Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption
The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples and will be collected every 30 or 60 min during the postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10 repetitions at 80% of 10-RM for both leg press and leg extension exercise.
Immediately after completion of the exercise bout, participants will consume 3 whole eggs or an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark the start of the postprandial phase (t=0 min) and additional muscle biopsies will be collected at t=120 and 300 min.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Urbana, Illinois, États-Unis, 61801
- Freer Hall
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male
- Aged 18-35 years
- Healthy, active (self-reported to exercise 2 - 4 times per week)
- BMI > 18.5 and < 25 kg/m2
Exclusion Criteria:
- Smoking
- Known allergies to egg consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
- A history of neuromuscular problems
- Diagnosed cognitive impairments
- Recent (1 year) participation in amino acid tracer studies
- Predisposition to hypertrophic scarring or keloid formation
- Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Whole eggs
After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
|
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Participants will ingestion whole eggs immediately after resistance exercise
|
|
Expérimental: Egg Whites
After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
|
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Participants will ingestion whole eggs immediately after resistance exercise
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fractional synthetic rate of myofibrillar proteins to whole egg and egg white ingestion
Délai: Postabsorptive for 3 hours, Postprandial for 5 hours
|
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental beverages.
This will allow us to assess the change from the postabsorptive to the postprandial period
|
Postabsorptive for 3 hours, Postprandial for 5 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phosphorylation of muscle anabolic signaling
Délai: Baseline and at 2 and 5 hours after protein ingestion
|
Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the whole egg and egg whites
|
Baseline and at 2 and 5 hours after protein ingestion
|
|
Exogenous rate of leucine appearance after ingestion of whole eggs and egg whites.
Délai: 5 hour postprandial phase
|
Dietary derived leucine availability will be measured during the 5 h postprandial phase to compare the dietary-derived leucine availability after whole egg and egg white ingestion.
|
5 hour postprandial phase
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Nicholas A Burd, Ph.D., Assistant Professor
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 15693
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .